Abstract

Introduction Initial high dose glucocorticosteroid (GC) treatment of transplant recipients induces changes in the glucocorticoid receptor (GR) that may affect the mode of action of the drug. We developed a TaqMan one-step RT-PCR quantification method to investigate the effect of bolus GC treatment on the structure of the GR complex by measuring the levels of GR isoform expression and FK binding protein 5 (FKBP5) transcription. Methods Peripheral blood mononuclear cells (PBMCs) were obtained before renal transplantation and immediately after the initial methylprednisolone treatment. Gene expression of the GR-α, -β, -P isoforms and FKBP5 were quantified using a simplex TaqMan relative quantification assay. Genotyping was performed using the TaqMan allele discrimination assay. Results The gene expression assay was validated and is efficient to detect extremely low quantity of GR-β expression. Increased expression of FKBP5 (14.01 + 11.52 folds), GR-α (1.47 + 1.00 folds), GR-β (6.21 + 5.71 folds) and GR-P (2.72 + 1.90 folds) were observed after steroid bolus. The GR haplotype A-T-G is significantly related to elevation of GRβ transcription ( p = 0.002). Patients’ hospitalization time after transplantation correlated with increment of GR-α ( p = 0.01) and FKBP5 ( p = 0.007) gene expression. The GR-β expression level is extremely low compared with the GR-α isoform. By contrast, the GR-P isoform is relatively abundantly expressed in PBMCs. Conclusion The method to measure GR isoform enabled us to determine that acute high-dose GC treatment alters the structure of the GR. The initial therapy with high dose steroid may induce a GC resistance phenotype. The modulatory role of the GR-P isoform is not fully defined but may provide another dimension in understanding the function of GR and the role of steroid in transplant immunosuppression.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.